NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma
Inclusion Criteria:
- Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the
decision has been taken by the investigator to prescribe Nexavar.
- Patients who failed cytokine therapy or who are not suitable for cytokines for whom
Nexavar is the first targeted drug treatment.
Exclusion Criteria:
- Prior targeted therapy for RCC
- Contraindications of Nexavar described in the Summary of Product Characteristics
(SPC).
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Duration of Nexavar treatment
Outcome Time Frame:
up to 3 years
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
16091
NCT ID:
NCT01508364
Start Date:
July 2012
Completion Date:
March 2015
Related Keywords:
- Carcinoma, Renal Cell
- renal cell carcinoma, first targeted therapy, observational study
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
